Direct oral anticoagulant safety during breastfeeding: a narrative review.

Maryam Daei Hossein Khalili Zinat Heidari

Published in: European journal of clinical pharmacology (2021)

According to the available limited data, dabigatran has the least excretion in human breast milk. Rivaroxaban and dabigatran both have acceptable milk excretion cutoffs, whereas apixaban milk excretion is greater than the maximum allowed range. Further well-designed studies with larger sample sizes are required to generate consistent comparable data and clarify benefits and risks of each DOAC during breastfeeding.

Keyphrases

atrial fibrillation
direct oral anticoagulants
venous thromboembolism
electronic health record
preterm infants
endothelial cells
big data
induced pluripotent stem cells
machine learning
data analysis
risk assessment